Literature DB >> 10551908

Usefulness of proton magnetic resonance spectroscopy in differentiating parkinsonian syndromes.

F Federico1, I L Simone, V Lucivero, D M Mezzapesa, M de Mari, P Lamberti, M Petruzzellis, E Ferrari.   

Abstract

Proton magnetic resonance spectroscopy ((1)H-MRS) was performed in patients with a clinical diagnosis of idiopathic Parkinson's disease (IPD), multiple system atrophy (MSA) or progressive supranuclear palsy (PSP) in order to assess metabolic differences between the three groups of patients. Single-volume (1)H-MRS, localized to the lentiform nucleus, was carried out in 19 IPD patients, 14 MSA patients, 11 PSP patients and 12 age-matched healthy subjects. The signals of N-acetylaspartate (NAA), choline-containing compounds (Cho) and creatine-phosphocreatine (Cr) were evaluated as peak area ratios. The NAA/Cho peak ratio was significantly reduced in MSA and in PSP patients compared to IPD patients and to controls. The NAA/Cr peak ratio was significantly reduced in MSA, in PSP and in IPD patients compared to controls, but only in MSA compared to IPD patients. The NAA reduction in the basal ganglia of MSA and PSP patients may reflect a neuronal loss or damage. Single-volume (1)H-MRS may be a useful tool in differentiating MSA and PSP from IPD patients.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10551908     DOI: 10.1007/s100720050035

Source DB:  PubMed          Journal:  Ital J Neurol Sci        ISSN: 0392-0461


  9 in total

1.  Magnetic resonance imaging in progressive supranuclear palsy.

Authors:  M Stamelou; S Knake; W H Oertel; G U Höglinger
Journal:  J Neurol       Date:  2010-12-22       Impact factor: 4.849

Review 2.  Magnetic resonance imaging for the diagnosis of Parkinson's disease.

Authors:  Beatrice Heim; Florian Krismer; Roberto De Marzi; Klaus Seppi
Journal:  J Neural Transm (Vienna)       Date:  2017-04-04       Impact factor: 3.575

3.  Proton Magnetic Resonance Spectroscopy for the Early Diagnosis of Parkinson Disease in the Substantia Nigra and Globus Pallidus: A Meta-Analysis With Trial Sequential Analysis.

Authors:  Wenbin Gu; Chen He; Juping Chen; Junchen Li
Journal:  Front Neurol       Date:  2022-06-16       Impact factor: 4.086

Review 4.  Parkinsonian syndromes.

Authors:  Francesco Federico; Domenico Maria Mezzapesa; Marco Petruzzellis
Journal:  Neurol Sci       Date:  2008-10       Impact factor: 3.307

5.  Multiple regional 1H-MR spectroscopy in multiple system atrophy: NAA/Cr reduction in pontine base as a valuable diagnostic marker.

Authors:  H Watanabe; H Fukatsu; M Katsuno; M Sugiura; K Hamada; Y Okada; M Hirayama; T Ishigaki; G Sobue
Journal:  J Neurol Neurosurg Psychiatry       Date:  2004-01       Impact factor: 10.154

Review 6.  MR spectroscopy in neurodegenerative disease.

Authors:  W R Wayne Martin
Journal:  Mol Imaging Biol       Date:  2007 Jul-Aug       Impact factor: 3.484

Review 7.  Magnetic resonance imaging markers for early diagnosis of Parkinson's disease.

Authors:  Silvia Marino; Rosella Ciurleo; Giuseppe Di Lorenzo; Marina Barresi; Simona De Salvo; Sabrina Giacoppo; Alessia Bramanti; Pietro Lanzafame; Placido Bramanti
Journal:  Neural Regen Res       Date:  2012-03-15       Impact factor: 5.135

Review 8.  Brain MR Contribution to the Differential Diagnosis of Parkinsonian Syndromes: An Update.

Authors:  Giovanni Rizzo; Stefano Zanigni; Roberto De Blasi; Daniela Grasso; Davide Martino; Rodolfo Savica; Giancarlo Logroscino
Journal:  Parkinsons Dis       Date:  2016-09-28

Review 9.  Magnetic resonance spectroscopy: an in vivo molecular imaging biomarker for Parkinson's disease?

Authors:  Rosella Ciurleo; Giuseppe Di Lorenzo; Placido Bramanti; Silvia Marino
Journal:  Biomed Res Int       Date:  2014-09-11       Impact factor: 3.411

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.